130:-based drugs. Using a proprietary technology platform, Peptides-to-Drugs (P2D), Jerini pursued disease indications for which limited, inadequate, or no treatment options exist. As a result, Jerini established a drug pipeline composed of its own programs as well as others in collaboration with partners. Jerini's commercialization strategy was to market new drugs in niche indications independently and in larger indications with partners. Jerini was acquired by
208:
Jerini's proprietary
Peptides-to-Drugs (P2D) technology was used to identify peptide drug lead structures and systematically transform them into peptidomimetic (injectable) and small-molecule (oral) drugs, depending on the indication. This enabled Jerini to develop novel drug candidates for diseases
209:
that were difficult to access using traditional drug discovery methods. The ability to produce both peptidomimetics and small molecule drugs as drug candidates has enabled the simultaneous development of drugs for acute and chronic treatments against the same target molecule (target).
27:
205:(AMD), the leading cause of vision loss and blindness in people over the age of 55 in developed countries. Jerini's compound (JSM 6427) has shown significant efficacy in combating disease progression in preclinical models.
360:
313:
457:
437:
452:
442:
153:. It went public on the Prime Standard of the Frankfurt Stock Exchange (JI4), and had raised a total of over 130 million Euro in public and private financing to date.
361:
https://web.archive.org/web/20150923190512/http://www.biotechnologie.de/BIO/Redaktion/PDF/de/Broschueren/bioregio2006,property=pdf,bereich=bio,sprache=de,rwb=true.pdf
364:
447:
226:
292:
242:
317:
462:
189:
Based on its P2D platform, Jerini established several in-house development programs, to address indications within the
137:
Jerini started operations in 1994. Jerini's subsidiaries Jerini US Inc. and JPT Peptide
Technologies GmbH, provider of
243:
https://web.archive.org/web/20110105052212/http://www.shire.com/shireplc/dlibrary/documents/AnnualReport2008.pdf
181:
in all member states of the
European Union in July 2008. The drug was granted FDA approval on August 25, 2011.
314:"Jerini Receives European Commission Approval for Firazyr (Icatibant) in the Treatment of HAE - Press release"
422:
170:
119:
246:
339:"FDA Approves Shire's FIRAZYR (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)"
202:
412:
142:
382:
264:
395:
338:
277:
146:
431:
190:
198:
178:
166:
150:
131:
83:
145:, were acquired by Theracode GmbH, Mainz in 2009. Jerini was financed with
26:
194:
138:
293:"TheraCode GmbH acquires JPT Peptide Technologies GmbH - Press release"
174:
162:
127:
123:
37:
126:, Germany, which focused on the discovery and development of novel
201:
therapeutic areas. The most advanced of these programs targeted
165:(icatibant), is an inhibitor of the action of the hormone
69:
Jochen Knolle, Chief
Scientific Officer, Head of R & D
417:
228:
Jerini erhält von der FDA ein Not
Approvable Letter
99:
89:
79:
52:
44:
33:
458:Medical and health organisations based in Berlin
438:Pharmaceutical companies disestablished in 2008
8:
453:Pharmaceutical companies established in 1994
19:
25:
18:
443:Manufacturing companies based in Berlin
291:JPT Peptide Technologies (2008-05-07).
218:
391:
380:
273:
262:
173:. This compound was in-licensed from
72:Berndt Modig, Chief Financial Officer
7:
448:Pharmaceutical companies of Germany
66:Adi Hoess, Chief Commercial Officer
177:in 2001. It has been approved for
14:
203:age-related macular degeneration
185:Peptides-to-Drugs (P2D) platform
423:European HAE information portal
1:
463:2008 mergers and acquisitions
16:German pharmaceutical company
62:Jens Schneider-Mergener, CEO
479:
24:
418:JPT Peptide Technologies
312:Jerini AG (2008-07-15).
161:Jerini's lead compound
341:(Press release). Shire
120:pharmaceutical company
320:on September 29, 2018
179:hereditary angioedema
370:on 23 September 2015
149:provided by TVM and
157:Firazyr (icatibant)
143:peptide microarrays
91:Number of employees
21:
390:Missing or empty
272:Missing or empty
252:on 5 January 2011
231:, 24. April 2008.
113:
112:
470:
413:Official website
400:
399:
393:
388:
386:
378:
376:
375:
369:
363:. Archived from
356:
350:
349:
347:
346:
335:
329:
328:
326:
325:
316:. Archived from
309:
303:
302:
300:
299:
288:
282:
281:
275:
270:
268:
260:
258:
257:
251:
245:. Archived from
238:
232:
223:
63:
40:, Germany (1994)
29:
22:
478:
477:
473:
472:
471:
469:
468:
467:
428:
427:
409:
404:
403:
389:
379:
373:
371:
367:
358:
357:
353:
344:
342:
337:
336:
332:
323:
321:
311:
310:
306:
297:
295:
290:
289:
285:
271:
261:
255:
253:
249:
240:
239:
235:
224:
220:
215:
187:
159:
147:venture capital
109:
92:
75:
61:
55:
48:Berlin, Germany
17:
12:
11:
5:
476:
474:
466:
465:
460:
455:
450:
445:
440:
430:
429:
426:
425:
420:
415:
408:
407:External links
405:
402:
401:
351:
330:
304:
283:
233:
225:Finanzen.net:
217:
216:
214:
211:
186:
183:
158:
155:
111:
110:
108:
107:
106:www.jerini.com
103:
101:
97:
96:
93:
90:
87:
86:
81:
77:
76:
74:
73:
70:
67:
64:
58:
56:
53:
50:
49:
46:
42:
41:
35:
31:
30:
15:
13:
10:
9:
6:
4:
3:
2:
475:
464:
461:
459:
456:
454:
451:
449:
446:
444:
441:
439:
436:
435:
433:
424:
421:
419:
416:
414:
411:
410:
406:
397:
384:
366:
362:
359:. 2015-09-23
355:
352:
340:
334:
331:
319:
315:
308:
305:
294:
287:
284:
279:
266:
248:
244:
241:. 2011-01-05
237:
234:
230:
229:
222:
219:
212:
210:
206:
204:
200:
196:
192:
191:ophthalmology
184:
182:
180:
176:
172:
168:
164:
156:
154:
152:
148:
144:
140:
135:
133:
129:
125:
121:
117:
105:
104:
102:
98:
94:
88:
85:
82:
78:
71:
68:
65:
60:
59:
57:
51:
47:
43:
39:
36:
32:
28:
23:
392:|title=
372:. Retrieved
365:the original
354:
343:. Retrieved
333:
322:. Retrieved
318:the original
307:
296:. Retrieved
286:
274:|title=
254:. Retrieved
247:the original
236:
227:
221:
207:
199:inflammatory
188:
160:
136:
115:
114:
45:Headquarters
171:B2 receptor
432:Categories
374:2022-08-20
345:2011-08-28
324:2008-07-28
298:2012-03-19
256:2022-09-16
213:References
167:bradykinin
95:139 (2006)
54:Key people
151:HealthCap
134:in 2008.
132:Shire plc
122:based in
116:Jerini AG
84:icatibant
20:Jerini AG
383:cite web
265:cite web
195:oncology
139:peptides
80:Products
175:Aventis
169:on its
163:Firazyr
128:peptide
100:Website
34:Founded
197:, and
124:Berlin
118:was a
38:Berlin
368:(PDF)
250:(PDF)
396:help
278:help
141:and
434::
387::
385:}}
381:{{
269::
267:}}
263:{{
193:,
398:)
394:(
377:.
348:.
327:.
301:.
280:)
276:(
259:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
